Phase II Trial of Ivonescimab, a PD‑1/VEGF bispecific antibody, with FOLFOX in advanced gastroesophageal adenocarcinoma

Massachusetts General Hospital sponsors this single-arm, open-label Phase II study evaluating the combination of ivonescimab and FOLFOX chemotherapy (including 5‑fluorouracil inhibiting thymidylate synthase, oxaliplatin as a DNA synthesis inhibitor, and leucovorin as a 5‑FU modulator) in first-line treatment for patients with HER2‑negative advanced gastroesophageal adenocarcinoma. The trial assesses safety and efficacy over up to 2 years with initial monotherapy dosing.